Recombinant Human JAK2 protein, His-tagged
Cat.No. : | JAK2-3128H |
Product Overview : | Recombinant Human JAK2 protein(O60674)(752-1132aa), fused to N-terminal His tag, was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
Source : | E. coli |
Species : | Human |
Tag : | His |
Form : | If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. |
Molecular Mass : | 48.6 kDa |
Protein length : | 752-1132aa |
AA Sequence : | KPLSALDSQRKLQFYEDRHQLPAPK WAELANLINNCMDYEPDFRPSFRAI IRDLNSLFTPDYELLTENDMLPNMR IGALGFSGAFEDRDPTQFEERHLKF LQQLGKGNFGSVEMCRYDPLQDNTG EVVAVKKLQHSTEEHLRDFEREIEI LKSLQHDNIVKYKGVCYSAGRRNLK LIMEYLPYGSLRDYLQKHKERIDHI KLLQYTSQICKGMEYLGTKRYIHRD LATRNILVENENRVKIGDFGLTKVL PQDKEYYKVKEPGESPIFWYAPESL TESKFSVASDVWSFGVVLYELFTYI EKSKSPPAEFMRMIGNDKQGQMIVF HLIELLKNNGRLPRPDGCPDEIYMI MTECWNNNVNQRPSFRDLALRVDQI RDNMAG |
Purity : | Greater than 90% as determined by SDS-PAGE. |
Storage : | Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
Reconstitution : | Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. |
Gene Name : | JAK2 Janus kinase 2 [ Homo sapiens ] |
Official Symbol : | JAK2 |
Synonyms : | JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3; |
Gene ID : | 3717 |
mRNA Refseq : | NM_004972 |
Protein Refseq : | NP_004963 |
MIM : | 147796 |
UniProt ID : | O60674 |
Products Types
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionJAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.
Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.
JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.
JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.
JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.
Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.
Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).
Customer Reviews (3)
Write a reviewQuick response from customer service.
Product performed as expected.
Satisfied with product quality.
Ask a Question for All JAK2 Products
Required fields are marked with *
My Review for All JAK2 Products
Required fields are marked with *
Inquiry Basket